Epidemiologic analysis of breast and gynecologic cancers
- PMID: 9108587
Epidemiologic analysis of breast and gynecologic cancers
Abstract
This review focuses on etiologic factors and hormonal correlates of the three major gynecologic cancers-uterine cervix, uterine corpus and ovary- and breast cancer. The incidence rate of the three gynecologic cancers combined is only 40 percent of the breast cancer rate (43.6 vs 109.5 per 100,000), whereas the combined mortality rate is half that for breast cancer (14.3 vs 27.3 per 100,000). Cervical cancer is distinctive in that it's hormonal correlates are few; it exhibits the epidemiologic characteristics of a sexually transmitted disease. Integration of Human Papilloma Virus DNA types 16, 18 (or other) within the cellular genome has been identified in more than 80% of high grade cervical intraepithelial neoplasias and invasive carcinomas. Epithelial ovarian cancers occur most commonly in nulliparous, infertile women and familial carriers of BRCA1. Oral contraceptive (OC) use reduces ovarian cancer risk by at least one-half, a benefit which increases with increasing duration of use and persists for at least 15 years after discontinuation. Pregnancy and OCs suppress gonadotropin secretion, whereas fertility drugs enhance follicle-stimulating hormone production. These indicators of alterations in the hypothalmic-pituitary-ovarian axis provide some support for both the excess gonadotropin and the incessant ovulation theories of ovarian carcinogenesis. Endometrial carcinoma is the prototype hormonally-determined disease. Increased estrogen from either endogenous or exogenous sources increases risk. Lowering the estrogen load or adding progestin reduces risk. This explains the marked protection achieved by combined estrogen/progestin OC's and the dramatic increased risk uncurred by long-term estrogen replacement therapy (ERT). Breast tissue, also a target for sex steroid hormones, displays a more complex risk profile. Current ERT use increases breast cancer risk by about 30%; adding a progestin to the estrogen does not improve the situation (40% increased risk). Furthermore, OCs do not reduce breast cancer risk, but may increase it for current OC users under age 45. The magnitude of these hormonal effects is much smaller than that exhibited with endometrial cancer.
Similar articles
-
The prevention of breast cancer through reduced ovarian steroid exposure.Acta Oncol. 1992;31(2):167-74. doi: 10.3109/02841869209088898. Acta Oncol. 1992. PMID: 1622631 Review.
-
Hormone replacement therapy and cancer.Gynecol Endocrinol. 2001 Dec;15(6):453-65. Gynecol Endocrinol. 2001. PMID: 11826770 Review.
-
Researchers can now investigate long-term effects of OCs on cancer.Contracept Technol Update. 1985 Jan;6(1):7-12. Contracept Technol Update. 1985. PMID: 12279918
-
Cancer risks and the contraceptive pill. What is the evidence after nearly 25 years of use?Med J Aust. 1986 Feb 17;144(4):185-90. Med J Aust. 1986. PMID: 3511357 Review.
-
Neoplastic effects of oral contraceptives.Int J Fertil. 1991;36 Suppl 1:19-24. Int J Fertil. 1991. PMID: 1678377 Review.
Cited by 12 articles
-
The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis.J Cancer. 2020 Jan 13;11(6):1424-1435. doi: 10.7150/jca.32886. eCollection 2020. J Cancer. 2020. PMID: 32047549 Free PMC article.
-
Genetic links between endometriosis and cancers in women.PeerJ. 2019 Dec 20;7:e8135. doi: 10.7717/peerj.8135. eCollection 2019. PeerJ. 2019. PMID: 31879572 Free PMC article.
-
Shared heritability and functional enrichment across six solid cancers.Nat Commun. 2019 Jan 25;10(1):431. doi: 10.1038/s41467-018-08054-4. Nat Commun. 2019. PMID: 30683880 Free PMC article.
-
Prognostic role of HOTAIR in four estrogen-dependent malignant tumors: a meta-analysis.Onco Targets Ther. 2015 Jun 15;8:1471-82. doi: 10.2147/OTT.S84687. eCollection 2015. Onco Targets Ther. 2015. PMID: 26109871 Free PMC article.
-
Palmitoylethanolamide prevents metabolic alterations and restores leptin sensitivity in ovariectomized rats.Endocrinology. 2014 Apr;155(4):1291-301. doi: 10.1210/en.2013-1823. Epub 2014 Jan 15. Endocrinology. 2014. PMID: 24428531 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
-
Full Text Sources
-
Medical
-
Research Materials
-
Miscellaneous